PVR and neoplasm: Furthermore, the expression of CD155 confirmed the data of Inozume et al, revealing a different immunosuppressive mechanism triggered by the interaction between CD155 and inhibitory ITIM domains as TIGIT expressed by tumour infiltrating lymphocytes [39].